341 related articles for article (PubMed ID: 19590489)
1. Golimumab (simponi) for inflammatory arthritis.
Med Lett Drugs Ther; 2009 Jul; 51(1316):55-6. PubMed ID: 19590489
[No Abstract] [Full Text] [Related]
2. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
3. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
4. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
5. Golimumab.
Mazumdar S; Greenwald D
MAbs; 2009; 1(5):422-31. PubMed ID: 20065639
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Chovel-Sella A; Karplus R; Sella T; Amital H
Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of golimumab in the treatment of arthritis.
Fleischmann R
Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
[TBL] [Abstract][Full Text] [Related]
8. In brief: new indications for secukinumab (Cosentyx).
Med Lett Drugs Ther; 2016 Jun; 58(1496):76. PubMed ID: 27249098
[No Abstract] [Full Text] [Related]
9. Golimumab, the newest TNF-α blocker, comes of age.
Papagoras C; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2015; 33(4):570-7. PubMed ID: 25602858
[TBL] [Abstract][Full Text] [Related]
10. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
11. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
12. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Campas-Moya C
Drugs Today (Barc); 2010 Jan; 46(1):13-22. PubMed ID: 20200692
[TBL] [Abstract][Full Text] [Related]
13. A review on golimumab in the treatment of psoriatic arthritis.
Urdaneta M; Jethwa H; Sultan R; Abraham S
Immunotherapy; 2017 Sep; 9(11):871-889. PubMed ID: 28838285
[TBL] [Abstract][Full Text] [Related]
14. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
15. "Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?".
Fiocco U; Punzi L
Joint Bone Spine; 2011 Jul; 78(4):331-4. PubMed ID: 21353617
[No Abstract] [Full Text] [Related]
16. Golimumab and immunogenicity? 2010 and beyond.
Zidi I; Bouaziz A; Ben Amor N
Pharmazie; 2011 Apr; 66(4):233-43. PubMed ID: 21612149
[TBL] [Abstract][Full Text] [Related]
17. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
Rossini M; Viapiana O; Orsolini G; Fracassi E; Idolazzi L; Gatti D; Adami S; Govoni M
Reumatismo; 2015 Mar; 66(4):285-303. PubMed ID: 25829189
[TBL] [Abstract][Full Text] [Related]
18. Once-a-month injection approved to treat three types of arthritis.
Thompson CA
Am J Health Syst Pharm; 2009 Jun; 66(11):968. PubMed ID: 19451600
[No Abstract] [Full Text] [Related]
19. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Leu JH; Adedokun OJ; Gargano C; Hsia EC; Xu Z; Shankar G
Rheumatology (Oxford); 2019 Mar; 58(3):441-446. PubMed ID: 30412238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]